Remove 2018 Remove Compounding Remove Pharmaceutical Companies
article thumbnail

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Utilising content metrics to improve digital engagement

pharmaphorum

The report refers to data collected across 350+ global pharma companies between November 2020 through January 2021, and notes a 70% compound average growth rate in the volume of content managed in Veeva Vault PromoMats since 2018. Veeva is the global leader in cloud software for the life sciences industry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Medicinal cannabis: the route to good manufacturing practice registration

European Pharmaceutical Review

After the substance became legal in the UK in 2018, pharmaceutical companies have faced numerous obstacles to attain a fairer position in the industry. Advising companies, he emphasised that those “manufacturing cannabis-based medicines should not underestimate the scale of the challenge.” He founded Celadon in 2018.

article thumbnail

HPLC-MS/MS for NDMA impurity determination in sartans

European Pharmaceutical Review

In 2018, one batch of the generic drug valsartan was recalled due to unacceptable levels of the nitrosamine impurity NDMA. Nitrosamine impurities are undesirable organic compounds with genotoxic, carcinogenic and mutagenic activity. This was the first of numerous recalls due to N -nitrosamine impurities in these types of drug.

article thumbnail

PsychoGenics secures NIH contract to identify new pain therapeutics

Pharmaceutical Business Review

The HEAL Initiative is an NIH-wide effort launched in April 2018, aiming to accelerate scientific solutions to the crisis of opioid and stimulant use disorders and pain management. These collaborations have led to the discovery of several novel compounds that are now either in clinical trials or advanced preclinical development stages.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. Environ Sci Technol 2018, 52, 4, 1725–1734 [link].

article thumbnail

Evaluating NMR relaxometry for antibody identification

European Pharmaceutical Review

NMR relaxation methods distinguish between components (phases or compounds) that have different molecular mobilities For monoclonal antibodies, identification methodologies can employ chromatography, spectroscopy, isoelectric focusing, capillary electrophoresis and peptide mapping techniques. European Pharmaceutical Review.